Evidence map›Paper›PMID 37111638›Full record

ReviewPharmaceutics2023

3D Printed Pharmaceutical Systems for Personalized Treatment in Metabolic Syndrome.

Abdulsalam A Alqahtani, Mohammed Muqtader Ahmed, Abdul Aleem Mohammed, Javed Ahmad

Open access · goldAbstract readReview
In one paragraph

Review in Pharmaceutics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.7field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 25 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Abdulsalam A AlqahtaniDepartment of Pharmaceutics, College of Pharmacy, Najran University, Najran 11001, Saudi Arabia.ORCID 0000-0001-7243-8042
Mohammed Muqtader AhmedDepartment of Pharmaceutics, College of Pharmacy, Prince Sattam Bin Abdulaziz University, Al-Kharj 11942, Saudi Arabia.ORCID 0000-0001-6911-0652
Abdul Aleem MohammedDepartment of Pharmaceutics, College of Pharmacy, Najran University, Najran 11001, Saudi Arabia.ORCID 0000-0003-2601-7962
Javed AhmadDepartment of Pharmaceutics, College of Pharmacy, Najran University, Najran 11001, Saudi Arabia.ORCID 0000-0002-7025-751X
Najran University · SAPrince Sattam Bin Abdulaziz University · SA

Funding

Deanship of Scientific Research at Najran University, Saudi Arabia NU/NAR/MRC/11/2
6 · The paper itself

Abstract

The current healthcare system is widely based on the concept of "one size fit for all", which emphasizes treating a disease by prescribing the same drug to all patients with equivalent doses and dosing frequency. This medical treatment scenario has shown varied responses with either no or weak pharmacological effects and exaggerated adverse reactions preceded by more patient complications. The hitches to the concept of "one size fits all" have devoted the attention of many researchers to unlocking the concept of personalized medicine (PM). PM delivers customized therapy with the highest safety margin for an individual patient's needs. PM has the potential to revolutionize the current healthcare system and pave the way to alter drug choices and doses according to a patient's clinical responses, providing physicians with the best treatment outcomes. The 3D printing techniques is a solid-form fabrication method whereby successive layers of materials based on computer-aided designs were deposited to form 3D structures. The 3D printed formulation achieves PM goals by delivering the desired dose according to patient needs and drug release profile to achieve a patient's personal therapeutic and nutritional needs. This pre-designed drug release profile attains optimum absorption and distribution, exhibiting maximum efficacy and safety profiles. This review aims to focus on the role of the 3D printing technique as a promising tool to design PM in metabolic syndrome (MS).

Indexed as

3D printing techniquesdrug delivery approachesmetabolic syndromepersonalized medicinepharmaceutical products

Identifiers

PMID37111638
PMCPMC10144629
OpenAlexW4362610109

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.